# A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers

Source: https://onco.cc/ideas/idea-acc-metronomic-lmic-platform-trial/  
OnCo record `idea-acc-metronomic-lmic-platform-trial` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Frequent tiny doses of cheap old chemotherapy pills have shown surprising benefit in some cancers. A single large trial network in India and Africa could find out where this works and where it does not.

## Summary

Metronomic regimens (low-dose oral methotrexate, cyclophosphamide, celecoxib) cost a few dollars a month and need no infusion. Tata Memorial trials showed a survival benefit for metronomic maintenance in head and neck cancer, but evidence in other tumours is thin and mostly single-centre. A multi-country platform trial with a shared control arm, adding and dropping regimens and tumour types, would generate definitive answers and could be run largely by nurses.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: In at least two of five common LMIC tumour types, a metronomic regimen will improve overall survival over best supportive care or standard palliative chemotherapy at less than 5% of the drug cost.
- Rationale: Head-and-neck results and the biology of anti-angiogenic and immunomodulatory low-dose schedules give a plausible mechanism; the drugs are on every essential medicines list.
- Proposed test: Run a phase 3 platform across the National Cancer Grid and African partner sites with overall survival and quality of life as endpoints, with pre-specified futility stopping per arm.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (Most of the world has almost no cancer care): WHO fact sheet, Cancer: https://www.who.int/news-room/fact-sheets/detail/cancer

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- institutions: [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- terms: [Basket, umbrella, and platform trials](https://onco.cc/terms/basket-umbrella-platform/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- roadmaps: [Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs](https://onco.cc/roadmaps/chemotherapy-roadmap/), [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-acc-metronomic-lmic-platform-trial.json